Sage Therapeutics Inc (NASDAQ:SAGE) saw a downside of -0.20% to close Friday at $19.56 after subtracting -$0.04 on the day. The 5-day average trading volume is 1,290,060 shares of the company’s common stock. It has gained $21.06 in the past week and touched a new high 1 time within the past 5 days. An average of 1,489,185 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 1,982,506.
SAGE’s 1-month performance is -0.96% or -$0.19 on its low of $19.28 reached on 09/21/23. The company’s shares have touched a 52-week low of $16.51 and high of $59.99, with the stock’s rally to the 52-week high happening on 06/12/23. YTD, SAGE has lost -48.72% or -$18.58 and has reached a new high 17 times. However, the current price is down -67.39% from the 52-week high price.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
SAGE stock investors last saw insider trading activity on Aug 09.JONAS JEFFREY M (Director) most recently sold 11,643 shares at $44.61 per share on Feb 10. This transaction cost the insider $519,413.
Valuation Metrics
SAGE stock has a beta of 1.13. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 112.95 while the price-to-book (PB) in the most recent quarter is 1.19.
Sage Therapeutics Inc’s quick ratio for the period ended June 29 was 10.99, with the current ratio over the same period at 10.99. In terms of profitability, the gross margin trailing 12 months is 80.87%. The trailing 12-month EBITDA margin is -7102.09% while for the period ending June 29, Sage Therapeutics Inc’s operating margin was -5990.25%. The firm’s gross profit as reported stood at $6.87 million against revenue of $7.69 million.
Earnings Surprise
For the quarterly period ending June 29 this year, Net income and sales went down compared to those figures reported in the previous quarter. Net income grew 21.25% to -$160.33 million, while revenue of -$146.83 million was 8.42% off the previous quarter. Analysts expected SAGE to announce -$2.55 per share in earnings in its latest quarter, but it posted -$2.68, representing a -5.10% surprise. EBITDA for the quarter stood at more than -$174.52 million. SAGE stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 97.91 million, with total debt at $8.73 million. Shareholders hold equity totaling $59.88 million.
Let’s look briefly at Sage Therapeutics Inc (SAGE) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 22 September was 33.15% to suggest the stock is trending Neutral, with historical volatility in this time period at 56.88%.
The stock’s 5-day moving average is $19.96, reflecting a -6.95% or -$1.46 change from its current price. SAGE is currently trading -1.06% above its 20-day SMA, -59.79% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -58.90% and SMA200 by-55.06%.
Stochastic %K and %D was 6.06% and 10.82% and the average true range (ATR) pointed at 1.02. The RSI (14) points at 32.80%, while the 14-day stochastic is at 5.98% with the period’s ATR at 1.16. The stock’s 9-day MACD Oscillator is pointing at -1.25 and -1.30 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Sage Therapeutics Inc (NASDAQ: SAGE), Needham downgraded it to a Hold rating. They previously had a Buy rating on the stock. Analysts offering their rating for SAGE stock have a consensus rating for the stock as Hold. Currently, 0 brokerage advisors rate SAGE as a “sell,”, while 17 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 4 have offered a “buy” rating.
What is SAGE’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $18.00 and a high of $79.00, with their median price target at $22.00. Looking at these predictions, the average price target given by analysts is for Sage Therapeutics Inc (SAGE) stock is $25.53.
